Studies on the antigenicity of an inactivated, aluminum hydroxide adjuvant equine influenza vaccine.
An inactivated, aluminum hydroxide adjuvant equine influenza vaccine was tested in horses and guinea pigs to determine the levels of antigen that would elicit maximum serological responses. Vaccine containing serial twofold increments of A/Equi-1/Prague and A/Equi-2/Miami strains of equine influenza virus was administered to random groupings of both types of test animals. The hemagglutination inhibition antibody response for each group was then measured. Results in horses and guinea pigs were compared to determine if the equine serological values could be related to a potency test in laboratory animals. The highest mean hemagglutination inhibition antibody response in horses occurred in groups vaccinated, respectively, with 128 or 256 hemagglutination units of A/Equi-1 and 512 or 1024 hemagglutination units of A/Equi-2 antigen. Groups vaccinated with further two- or fourfold increases in these antigens had mean hemagglutination inhibition titers that were somewhat lower than the maximum levels. When graded doses of vaccine were given to guinea pigs, their hemagglutination inhibition antibody titers reached a plateau of maximum values, similar to the serological response in vaccinated horses. Test horses remained clinically free from signs of equine influenza during the year following vaccination and no untoward post-vaccination reactions were observed.
D000276:Adjuvants, Immunologic; D000536:Aluminum Hydroxide; D000818:Animals; D000917:Antibody Formation; D000956:Antigens, Viral; D006168:Guinea Pigs / Q000276:immunology; D006385:Hemagglutination Inhibition Tests; D006736:Horses / Q000276:immunology*; D009980:Influenza A virus / Q000276:immunology; D007252:Influenza Vaccines
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D007252:Influenza Vaccines; D000536:Aluminum Hydroxide